Partnering for success

Beyond Curve’s pipeline there are multiple applications for our disease agnostic Microcycle platform to revolutionize drug discovery, with clear opportunities for collaborative research and development with partners that have a depth of knowledge in target biology and expertise in drug development.

Curve welcomes the opportunity to collaborate with pharma partners to identify novel hits and leads against their high-priority targets in a broad range of indications.

Discuss partnering opportunities

Science

Revolutionary Platform

Our Microcycle^® platform allows direct screening for biologically active hits inside mammalian cells and facilitates small molecule hit-to-lead programmes.

Pipeline

Challenging cancer targets

We are currently deploying our platform to build a pipeline of first-in-class small molecule drugs to address high priority cancer targets that have evaded conventional discovery approaches.